Intravesically Administered BCG May Have Antiangiogenic Effects on Urinary Concentrations of Basic Fibroblast Growth Factor ( bFGF), Vascular Endothelial Growth Factor (VEGF) and Interleukin (IL-8)
N/A
N/A
Both
Bladder Cancer
Trial Information
Intravesically Administered BCG May Have Antiangiogenic Effects on Urinary Concentrations of Basic Fibroblast Growth Factor ( bFGF), Vascular Endothelial Growth Factor (VEGF) and Interleukin (IL-8)
200 patients that are candidates for intravesical BCG therapy and 20 control patients with
no history of malignancy will be enrolled. The study group wol;; be asked to provide a
urine sample just prior to receiving their first BCG treatment(week # 1) and just prior to
receiving their last (week # 6) BCG treatment. The control patients will provide one urine
sample only. Samples will be analysed by enzyme-linked immunosorbant assay(ELISA). clinical
data will be reviewed on tumor stage and grade prior to BCG, timme to recurrence, tumor
stage and grade of recurrence, time to disease progression and death, cause of death and
total follow-up time.
Inclusion Criteria:
200 study group 1. Must be a candidate for BCG therapy. 20 control group 1. No history of
malignancy.
Exclusion Criteria:
- N/A
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Jonathan Izawa, MD, FRCSC
Investigator Role:
Principal Investigator
Investigator Affiliation:
LHRI
Authority:
Canada: Health Canada
Study ID:
R-03-275
NCT ID:
NCT00216814
Start Date:
October 2003
Completion Date:
September 2007
Related Keywords:
- Bladder Cancer
- antiangiogenic effects of bcg treatment and prognosis
- Urinary Bladder Neoplasms
Name | Location |
|---|
